Table 4.
Summary of current gas therapy nanosystems for RA therapy.
| Gas | Nano-system | Generation NPs | Targets | Animal model | Mechanisms | Effects | Key features | Limitations | Refs. |
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
Elevates articular O2 levels, shifts macrophage polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotype, and alleviates joint inflammation, swelling, and bone erosion. | Spatiotemporally precise O2 generation; good biosafety. | Limited long-term O2 generation and challenging scale-up production. | [45] |
|
|
|
|
|
Reduces joint swelling, mitigates bone damage, decreases paw thickness and clinical scores, and ameliorates metabolic dysregulation in RA rats. | Pathological microenvironment-responsive release; dual anti-inflammatory and bone-protective effects. | Limited drug loading capacity; potential toxicity risk of calcium peroxide. | [46] | |
|
|
|
|
|
Effectively alleviates joint inflammation and erosion, reduces arthritis scores and paw swelling, restores rat body weight, and mitigates bone and cartilage damage. | Strong targeting capability; ROS-responsive drug release; good biocompatibility. | Challenging manufacturing process. | [47] | |
|
|
|
|
|
Significantly reduces paw thickness, joint diameter, synovitis scores, and bone erosion area in mice, effectively alleviating joint inflammation, cartilage damage, and osteolysis. | Synergistic hypoxia alleviation and ROS scavenging. | Unclear biosafety and long-term toxicity; insufficient drug delivery efficiency and targeting. | [48] | |
|
|
|
|
|
Markedly reduces joint swelling, decreases oxidative stress markers, protects articular bones from inflammatory damage, and inhibits cartilage erosion. | High catalytic activity in acidic environments; dual-function regulation (antioxidant/oxygenation); good biocompatibility. | Low crystallinity potentially compromises long-term stability and catalytic efficiency is still inferior to natural enzymes. | [49] | |
|
|
|
|
|
Alleviates localized hyperinflammation and synovial hyperplasia, reduces ROS levels and oxidative stress, enhances prosthesis osseointegration, and promotes bone regeneration. | Dual ROS scavenging and H2O2-driven O2 production; strong catalytic stability. | Unclear long-term biosafety and potential effects of in vivo degradation products. | [49] | |
|
|
|
|
|
Effectively controls inflammation, modulates macrophage phenotype switching, alleviates joint hypoxia, and reduces bone damage and cartilage degradation. | H2O2-driven nanomotor in RAM enables ROS scavenging, O2 generation/imaging, and enhanced diffusion. | Challenges in precision control over movement and depth, and unknown long-term safety profile. | [50] | |
|
|
|
|
|
|
High photothermal conversion efficiency. | Potential long-term toxicity risks. | [51] | |
|
|
|
|
|
Effectively alleviates joint hypoxia, inflammation, and pathological symptoms while modulating macrophage phenotype switching. | Synergistic effect: ceria NPs eliminate ·OH intermediates from manganese ferrite NPs' O2 generation. | Unclear long-term biosafety and inadequate targeting capability. | [52] | |
|
|
|
|
|
Targeted intra-articular O2 delivery reverses hypoxia, sensitizes activated T cells to cuproptosis, and thereby relieves RA inflammation and bone erosion. | Dual-action mechanism: immunosuppression and cytotoxicity; intelligent activation-responsive therapeutic strategy; high biocompatibility. | Long-term safety and pharmacokinetics remain to be established; mechanistic complexity. | [53] | |
|
|
|
|
|
|
Reduces local oxidative stress, downregulates inflammatory factors, decreases joint diameter, and alleviates synovitis and cartilage erosion. | Synergistic therapy and active propulsion; ultrasound imaging capability. | Water-dependent reaction with limited persistence; manufacturing complexity. | [54] |
|
|
|
|
|
Alleviates inflammatory responses, reduces cartilage degradation, synovial hyperplasia, and inflammatory cell infiltration. | Plasmon-enhanced photocatalysis, significantly boosted H2 production and ROS scavenging. | Complex synthesis and non-biodegradability of gold nanorods. | [55] | |
|
|
|
|
|
Alleviates oxidative stress in RA mice, significantly mitigates joint damage, and suppresses overall arthritis severity. | High drug loading; on-demand activation; PA imaging capability; combined PTT. | Costly materials and complex synthesis; unknown long-term metabolic fate. | [56] | |
|
|
|
|
|
Significantly alleviates joint swelling, mitigates bone erosion, and exerts synergistic antioxidant, anti-inflammatory, and bone-remodelling effects. | Antioxidant and anti-inflammatory with bone homeostasis regulation; good biocompatibility. | Large-scale production challenges; individual variations affect hydrolysis efficiency. | [57] | |
|
|
|
|
|
|
Effectively reverses RA-induced bone erosion, alleviates joint inflammation, and restores immune homeostasis. | On-demand activation; well-defined structure with high reproducibility; NIR-II imaging. | Long-term safety remains unknown. | [58] |
|
|
|
|
|
|
Precise NO/CO co-modulation, multi-pathway anti-inflammatory synergy. | Stability and scale-up challenges of micelles. | [59] | |
|
|
|
|
|
|
Reduces joint inflammation and repairs degeneration by alleviating symptoms, lowering biomarkers, and restoring macrophage homeostasis. | GSH-responsive on-demand activation; NIR-II FL/PA imaging. | Precise control of gas therapy; unclear long-term metabolic pathway. | [60] |